中国癌症杂志 ›› 2021, Vol. 31 ›› Issue (2): 108-113.doi: 10.19401/j.cnki.1007-3639.2021.02.004

• 论著 • 上一篇    下一篇

腺苷酸激酶4在肺腺癌中的表达及其临床意义

田 华 1 ,何小勇 2 ,王道猛 2 ,杨永国 1 ,梅 霞 1 ,钱 斌 2   

  1. 1. 扬州市江都人民医院病理科,江苏 扬州 225200 ;
    2. 扬州市江都人民医院胸外科,江苏 扬州 225200
  • 出版日期:2021-02-28 发布日期:2021-03-02
  • 通信作者: 钱 斌 E-mail: 18952531085@189.cn

Expression of adenylate kinase 4 in lung adenocarcinoma and its clinical significance

TIAN Hua 1 , HE Xiaoyong 2 , WANG Daomeng 2 , YANG Yongguo 1 , MEI Xia 1 , QIAN Bin#br#   

  1. 1. Department of Pathology, Jiangdu People’s Hospital of Yangzhou, Yangzhou 225200, Jiangsu Province, China; 2. Department of Thoracic Surgery, Jiangdu People’s Hospital of Yangzhou, Yangzhou 225200, Jiangsu Province, China
  • Published:2021-02-28 Online:2021-03-02
  • Contact: QIAN Bin E-mail: 18952531085@189.cn

摘要: 背景与目的:腺苷酸激酶(adenylate kinase 4,AK4)是一种调节腺嘌呤核苷酸代谢和体内稳态的关键调节酶。研究发现,AK4可促进肺癌细胞的侵袭与转移,并与肺癌患者预后不良密切相关,但AK4在肺腺癌发生、发展过程中的作用尚不清楚。研究AK4在肺腺癌中表达的变化,以及与患者临床病理学特征之间的关系,探讨AK4在肺腺癌发生、发展过程中的作用。方法:应用免疫组织化学EnVision法研究江苏省扬州市江都人民医院2017年1月—2019年12月胸外科手术切除的297例肺腺癌不同阶段病变,其中浸润性腺癌(invasive adenocarcinoma,IA)152例,微浸润性腺癌(microinvasive adenocarcinoma,MIA)52例,原位腺癌(adenocarcinoma in situ,AIS)60例,非典型腺瘤样增生(atypical adenomatous hyperplasia,AAH)33例,以及30例正常肺组织中AK4的表达。结果:AK4在AAH、AIS、MIA和IA中的表达率分别为63.6%、75.0%、71.1%和81.6%,均明显高于正常肺组织,差异有统计学意义(P<0.01),但AK4表达率在AAH、AIS、MIA和IA之间差异无统计学意义(P>0.05);AK4表达率在有淋巴结转移者高于无淋巴结转移者(P<0.05),AK4高表达与肺腺癌pTNM分期密切相关(P<0.05)。AK4表达率与肺腺癌患者性别、年龄、吸烟状态、肿瘤部位及大小、脉管侵犯和胸膜侵犯无关(P>0.05)。结论:AK4不仅参与肺腺癌的早期发生,还参与肺腺癌的进展。AK4可望作为肺腺癌早期诊断和评估疾病进展的一种生物标志物。

关键词: 肺肿瘤, 腺癌, 腺苷酸激酶, 临床病理学特征

Abstract: Background and purpose: Adenylate kinase 4 (AK4) is a key regulation enzyme that regulates the metabolism of adenylate and maintains homeostasis in vivo. Some studies show that AK4 promotes the invasion and metastasis of lung cancer cells and correlates with the poor prognosis of patients with lung carcinoma. However, the role of AK4 in the occurrence and development of early-stage lung adenocarcinoma is not clear. The purpose of this study was to investigate the change of AK4 expression in the carcinogenesis of early-stage lung adenocarcinoma and its relationship with clinicopathologic features, and to explore the role of AK4 in the carcinogenesis and progression of early-stage lung adenocarcinoma. Methods: Immunohistochemical EnVision method was used to detect the expression of AK4 in 297 cases of lung adenocarcinoma at different stages treated in Jiangdu People’s Hospital of Yangzhou from Jan. 2017 to Dec. 2019, including invasive adenocarcinoma (IA) (n=152), minimally invasive adenocarcinoma (MIA) (n=52), adenocarcinoma in situ (AIS) (n=60) and atypical adenomatous hyperplasia (AAH) (n=33), and normal tissues (n=30). Results: The expression rates of AK4 in AAH, AIS, MIA, and IA were 63.6%, 75.0%, 71.1%, and 81.6%, respectively, which were higher than in normal lung tissues, and the difference was statistically significant (P<0.01). However, there was no significant difference in expression of AK4 among AAH, AIS, MIA and IA (P>0.05). The expression rate of AK4 in lung adenocarcinoma with lymph node metastasis was higher compared with those without lymph node metastasis (P<0.05), and expression of AK4 was related to pTNM stage (P<0.05). However, expression of AK4 was related to gender, age, smoking status, tumor location and size, vascular invasion and pleura invasion (P>0.05). Conclusion: AK4 may be involved in not only early occurrence of lung adenocarcinoma, but also the progression of lung adenocarcinoma. AK4 may be a biomarker for the early diagnosis of lung adenocarcinoma and evaluation of disease progression.

Key words: Lung neoplasm, Adenocarcinoma, Adenylate Kinase, Clinical pathological features